MCC950 is a small-molecule NLRP3 inhibitor that has inhibited inflammasome activation in rodent PD models leading to substantial neuroprotection, mitigation in motor deficits, and accumulation of α-synuclein aggregates (Figure 3, Table 2; Gordon et al., 2018). This evidence concerns the gene NLRP3 and Parkinson disease.